Abstract
Objective: In a phase II clinical trial in nine obese, insulin-resistant humans, we observed that treatment with KDT501, a novel isohumulone drug, increased total and high-molecular weight (HMW) adiponectin in plasma. The objective was to determine whether KDT501 increased adiponectin secretion from subcutaneous white adipose tissue (SC WAT) and the underlying mechanism(s).
Methods: Nine obese participants with either prediabetes or with normal glucose tolerance plus three features of metabolic syndrome were part of the study. SC WAT biopsies were performed before and after 28 days of KDT501 treatment in a clinical research setting. In addition, a cold stimulus was used to induce thermogenic gene expression. Adiponectin secretion was measured, and gene expression of 130 genes involved in adipose tissue function was determined. The effect of KDT501 on adipocyte mitochondrial function was analyzed in vitro.
Results: SC WAT explants secreted more total and HMW adiponectin after KDT501 treatment (P < 0.05). After KDT501 treatment, a number of genes involved in thermogenesis and lipolysis were induced by cold (P < 0.05). KDT501 also potentiated β-adrenergic signaling (P < 0.001) and enhanced mitochondrial function in adipocytes (P < 0.001).
Conclusion: KDT501 induced adiponectin secretion posttranscriptionally and increased gene expression of thermogenic and lipolytic genes in response to cold stimulation. These beneficial effects on SC WAT may be explained by the ability of KDT501 to potentiate β-adrenergic signaling and enhance mitochondrial function in adipocytes.
Clinical Trial Registration: https://www.ClinicalTrials.gov, ID number: NCT02444910.
Document Type
Article
Publication Date
9-29-2017
Digital Object Identifier (DOI)
https://doi.org/10.3389/fendo.2017.00255
Funding Information
This work was supported by Kindex Pharmaceuticals, National Institute of Diabetes and Digestive and Kidney Diseases (DK107646), National Institute of General Medical Sciences (P20GM103527), NIH Office of the Director (1S10OD16357), and National Center for Advancing Translational Sciences (CTSA grant UL1TR001998).
Related Content
The Supplementary Material for this article can be found online at https://www.frontiersin.org/article/10.3389/fendo.2017.00255/full#supplementary-material.
Repository Citation
Finlin, Brian S.; Zhu, Beibei; Kok, Bernard P.; Godio, Cristina; Westgate, Philip M.; Grayson, Neile; Sims, Robert; Bland, Jeffrey S.; Saez, Enrique; and Kern, Philip A., "The Influence of a KDT501, a Novel Isohumulone, on Adipocyte Function in Humans" (2017). Internal Medicine Faculty Publications. 128.
https://uknowledge.uky.edu/internalmedicine_facpub/128
Supplementary Tables
Included in
Endocrinology, Diabetes, and Metabolism Commons, Medical Genetics Commons, Medical Molecular Biology Commons, Pharmaceutics and Drug Design Commons
Notes/Citation Information
Published in Frontiers in Endocrinology, v. 8, 255, p. 1-11.
© 2017 Finlin, Zhu, Kok, Godio, Westgate, Grayson, Sims, Bland, Saez and Kern.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.